ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

In Brief: Adamson’s Appointment Official As DCCP Director; NCI Holds Current Spending To 12 Percent Level

October 23, 1981

New NCI Director Proposes $9 Million Community Cancer Centers Program.

September 8, 2006

HHS To Award “Micro-Grants” For Public Health Programs.

July 20, 2001

FDA’s Handling Of UFT Raises Questions About Agency’s Isolation, Grasp Of Science.

July 21, 2000

Vanderbilt-Ingram Wins NCI SPORE Grant

April 19, 2002

After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant

July 11, 2014